Skip to main content
ARTL
NASDAQ Life Sciences

Artelo Biosciences Terminates ATM Program After Raising $451K, Amidst Going Concern

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$1.469
Mkt Cap
$3.407M
52W Low
$1.41
52W High
$85.8
52W Position info
4.2% above low
Off High info
98% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

ARTL is trading near its 52-week low of $1.41 (4.2% above the low) on light trading volume (0.2× avg).

Summary

Artelo Biosciences terminated its At-The-Market (ATM) offering agreement with R.F. Lafferty & Co., Inc., after selling 50,858 shares and raising $451,526.95 in gross proceeds. This comes as the company faces a going concern warning and its stock trades near 52-week lows.


Key Events · Financing and Capital Events · ARTL

  • ATM Program Terminated

    Artelo Biosciences terminated its At-The-Market (ATM) offering agreement with R.F. Lafferty & Co., Inc., effective May 18, 2026. The program had authorized sales of up to $6.5 million.

  • Proceeds Raised

    Prior to termination, the company sold 50,858 shares of common stock through the ATM program, generating gross proceeds of $451,526.95.

  • Financial Context

    The termination occurs while the company has an active going concern warning and its stock is trading near 52-week lows, indicating ongoing capital challenges.


Analysis · ARTL · Life Sciences

This filing is important because it details the termination of a capital-raising mechanism for a company under a going concern warning. While the company did raise over $451,000 through the ATM program, the termination of the agreement, which had a potential value of up to $6.5 million, suggests challenges in utilizing this financing method or a strategic pivot. For a company with limited cash and a going concern, closing off a potential source of funds, even if underutilized, is a negative signal regarding its ability to secure necessary capital.

How filings like this one have moved

In the 30 days to Nov 3, 2026, 32.3% of the 2077 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ARTL was trading at $1.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4M. The 52-week trading range was $1.41 to $85.80. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ARTL - Latest Insights

ARTL
Oct 09, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.19
Real-time Price: $2.28 info
Change: -$0.910 (-29%) info
Market Cap: $1.249M info
ARTL
Sep 23, 2026, 1:46 PM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $7.84
Real-time Price: $2.28 info
Change: -$5.56 (-71%) info
Market Cap: $1.249M info
ARTL
Sep 16, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.02
Real-time Price: $2.28 info
Change: -$2.74 (-55%) info
Market Cap: $1.249M info
ARTL
Aug 27, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.658
Real-time Price: $2.28 info
Change: Reverse Stock Split info
Market Cap: $1.249M info
ARTL
Aug 27, 2026, 8:03 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $0.6899
Real-time Price: $2.28 info
Change: Reverse Stock Split info
Market Cap: $1.249M info